Cargando…

Synaptic proteins in CSF relate to Parkinson’s disease stage markers

Recent findings of morphological and functional changes in Parkinson’s disease brains have shown altered synapse formation, but their role in cognitive decline is still an area under exploration. Here we measured the concentration of three key synaptic proteins, Rab3A, SNAP25 and neurogranin by enzy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bereczki, Erika, Bogstedt, Anna, Höglund, Kina, Tsitsi, Panagiota, Brodin, Lovisa, Ballard, Clive, Svenningsson, Per, Aarsland, Dag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445607/ https://www.ncbi.nlm.nih.gov/pubmed/28649607 http://dx.doi.org/10.1038/s41531-017-0008-2

Ejemplares similares

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
por: Green, Holly, et al.
Publicado: (2019)

Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson’s disease
por: Waldthaler, Josefine, et al.
Publicado: (2019)

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
por: Svenningsson, Per, et al.
Publicado: (2018)

Reading Alterations in Parkinson's Disease Indicate Worse Cognitive Status
por: Tsitsi, Panagiota, et al.
Publicado: (2023)

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
por: Bloniecki, Victor, et al.
Publicado: (2020)

Pupil light reflex dynamics in Parkinson’s disease
por: Tsitsi, Panagiota, et al.
Publicado: (2023)

Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson’s Disease
por: Tsitsi, Panagiota, et al.
Publicado: (2021)

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
por: Stubendorff, Kajsa, et al.
Publicado: (2014)

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies
por: Bogstedt, Anna, et al.
Publicado: (2015)

Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer’s Disease
por: Smailovic, Una, et al.
Publicado: (2021)

Reduction of spontaneous cortical beta bursts in Parkinson’s disease is linked to symptom severity
por: Vinding, Mikkel C, et al.
Publicado: (2020)

Psychiatric and neuropsychiatric syndromes and COVID-19
por: Velayudhan, Latha, et al.
Publicado: (2020)

Mental health of people living with dementia in care homes during COVID-19 pandemic
por: Velayudhan, Latha, et al.
Publicado: (2020)

Attenuated beta rebound to proprioceptive afferent feedback in Parkinson’s disease
por: Vinding, Mikkel C., et al.
Publicado: (2019)

Impaired synaptic function is linked to cognition in Parkinson's disease
por: Selnes, Per, et al.
Publicado: (2017)

Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers
por: Grambaite, Ramune, et al.
Publicado: (2013)

Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease
por: Tsitsi, Panagiota, et al.
Publicado: (2021)

Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
por: te Vruchte, Danielle, et al.
Publicado: (2022)

Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease
por: Ran, Caroline, et al.
Publicado: (2017)

Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease
por: Paslawski, Wojciech, et al.
Publicado: (2023)

Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial
por: Husebo, Bettina S, et al.
Publicado: (2011)

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
por: Gibson, Lucy L., et al.
Publicado: (2023)

Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias
por: Xing, Huayang, et al.
Publicado: (2016)

Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
por: Mueller, Christoph, et al.
Publicado: (2020)

Ependymal cells-CSF flow regulates stress-induced depression
por: Seo, Ji-Seon, et al.
Publicado: (2021)

Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM)
por: Erdal, Ane, et al.
Publicado: (2018)

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2021)

Associations Between Fluctuations in Daytime Sleepiness and Motor and Non‐Motor Symptoms in Parkinson's Disease
por: Höglund, Arja, et al.
Publicado: (2020)

Neurodegenerative Disease Associated Pathways in the Brains of Triple Transgenic Alzheimer’s Model Mice Are Reversed Following Two Weeks of Peripheral Administration of Fasudil
por: Killick, Richard, et al.
Publicado: (2023)

Patients are doing it for themselves: A survey on disease-specific knowledge acquisition among people with Parkinson’s disease in Sweden
por: Riggare, Sara, et al.
Publicado: (2017)

Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM)
por: Erdal, Ane, et al.
Publicado: (2018)

A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey
por: McGoohan, Katie, et al.
Publicado: (2020)

Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2022)

Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
por: Ran, Caroline, et al.
Publicado: (2016)

Nonmotor Symptoms of Parkinson's Disease
por: Rektorova, Irena, et al.
Publicado: (2011)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

COSMOS—improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial
por: Husebo, Bettina S., et al.
Publicado: (2015)

Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults
por: Creese, Byron, et al.
Publicado: (2021)

Late‐life onset psychotic symptoms and incident cognitive impairment in people without dementia: Modification by genetic risk for Alzheimer's disease
por: Creese, Byron, et al.
Publicado: (2023)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ppv5b98b1pi53fh0ahunn57skj